Financial Performance - The company's revenue for Q3 2024 was ¥63,612,400.30, representing a year-over-year increase of 12.77%[2] - Total operating revenue for Q3 2024 reached ¥192,581,520.03, an increase of 12.2% compared to ¥170,495,925.88 in Q3 2023[16] - The net profit attributable to shareholders for Q3 2024 was ¥9,614,817.99, a decrease of 12.36% compared to the same period last year[2] - Net profit for Q3 2024 was ¥34,066,532.24, down 17.6% from ¥41,294,028.25 in Q3 2023[17] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥8,054,277.30, showing a slight increase of 0.66% year-over-year[2] - Operating costs for Q3 2024 amounted to ¥160,706,213.91, up 12.1% from ¥143,337,161.46 in Q3 2023[16] - Research and development expenses increased to ¥10,025,178.80, a rise of 91.5% compared to ¥5,227,257.77 in Q3 2023[16] - The company reported a decrease in other income to ¥5,205,516.81 from ¥12,885,308.95 in the previous year, a decline of 59.6%[16] Cash Flow and Investments - The operating cash flow for the year-to-date period reached ¥46,082,996.64, reflecting a significant increase of 48.02% compared to the previous year[6] - The net cash flow from operating activities for the current period is ¥46,082,996.64, an increase from ¥31,132,671.06 in the previous period, reflecting a growth of approximately 48.1%[19] - Cash inflow from operating activities totaled ¥212,049,594.39, slightly up from ¥211,702,938.91, indicating a marginal increase of 0.16%[19] - Cash outflow from operating activities decreased to ¥165,966,597.75 from ¥180,570,267.85, representing a reduction of about 8.1%[19] - The net cash flow from investment activities was negative at -¥108,582,303.54, a significant decline from a positive ¥11,020,283.95 in the previous period[21] - Cash outflow for investment activities was ¥879,924,085.19, down from ¥1,008,238,717.35, showing a decrease of approximately 12.7%[21] - The company received cash from the recovery of investments amounting to ¥765,427,454.08, down from ¥1,012,000,000.00, reflecting a decline of approximately 24.4%[19] - The cash received from investment income was ¥5,914,327.57, down from ¥7,259,001.30, indicating a decrease of about 18.5%[19] - The company paid out ¥20,015,394.10 in dividends and interest, an increase from ¥12,928,630.88, representing a growth of approximately 55.5%[21] Assets and Liabilities - The total assets at the end of the reporting period were ¥976,928,717.08, down 8.46% from the end of the previous year[2] - The company's total assets decreased to ¥976,928,717.08 from ¥1,067,195,971.50 in the previous year, reflecting a decline of 8.5%[15] - The total liabilities decreased to ¥78,416,311.28 from ¥84,332,557.25, a reduction of 7% year-over-year[15] - The equity attributable to shareholders decreased to ¥898,512,405.80, a decline of 8.58% compared to the previous year[2] - Deferred income tax assets stood at ¥7,486,943.88, slightly down from ¥7,587,915.47 in the previous year[15] - The company’s non-current assets totaled ¥527,160,277.37, an increase from ¥433,432,685.40 in the previous year, reflecting a growth of 21.6%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 7,496, with the largest shareholder holding 24.29% of the shares[7] - The company repurchased a total of 4,255,458 shares, accounting for 5.27% of the total share capital, with a total transaction amount of 98,386,018.14 RMB[12] - The company’s stockholder Zhang Jun holds 19,627,034 restricted shares, which will be released on February 23, 2025[10] - The company’s shareholder Shi Yingxiu holds 1,479,088 restricted shares, which will be released at a rate of 25% annually[10] Earnings Per Share - The basic earnings per share for Q3 2024 was ¥0.1252, down 7.81% year-over-year[2] - Basic earnings per share for Q3 2024 were ¥0.4351, down from ¥0.511 in Q3 2023[18]
西点药业(301130) - 2024 Q3 - 季度财报